<DOC>
	<DOCNO>NCT02736500</DOCNO>
	<brief_summary>The aim phase I-II study evaluate efficacy toxicity PRRT 177Lu-DOTATATE ( Lu-PRRT ) associate metronomic chemotherapy Capecitabine patient affect aggressive FDG-positive gastro-entero-pancreatic NET . Moreover analyze effect capecitabine metronomic schedule level circulate angiogenetic factor .</brief_summary>
	<brief_title>Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>Neuroendocrine tumor ( NETs ) relatively rare tumor , mainly originate digestive system , able produce bioactive amine hormone . NETs tend slow grow often diagnose metastatic . Treatment multidisciplinary individualize accord tumor type , burden , symptom . Therapeutic tool include surgery , interventional radiology , medical treatment somatostatin analogue , interferon , chemotherapy , new target drug ( everolimus , sunitinib ) radiolabelled somatostatin analogue . Despite option available , antiproliferative treatment option patient inoperable gastro-entero-pancreatic ( GEP ) NETs limit . PRRT radiolabelled somatostatin analogue 90Y-DOTATOC , 177Lu-DOTATATE ( 177Lu-DOTA-D-Phe1-Tyr3-octreotate ) , experiment 15 year center . The introduction PRRT , particularly , advent 177Lu-DOTATATE , break poor scenario available treatment NETs . Dosimetric study demonstrate 90Y-DOTATOC 177Lu-DOTATATE able deliver high radiation dos somatostatin receptor sst2-expressing tumor low dos normal organ . Clinical study demonstrate partial complete objective response 30 % patient obtain , great survival benefit include stable disease . Side effect may involve kidney bone marrow usually mild . Renal protection use minimize risk late decrease renal function . Recently , order increase objective response PRRT , combine treatment radiosensitizer capecitabine , propose test GEP-NET patient ' population . Capecitabine oral prodrug 5-fluorouracile ( 5-FU ) , active GEP tumor radiosensitizer . The find neo-angiogenesis shut also cytotoxic drug like capecitabine administer low frequent dos , constitutes rationale propose particular schedule chemotherapy , therefore , name `` metronomic '' `` anti-angiogenic '' . Based report experience , investigator think offer combine therapy aggressive , metabolically active tumor , patient positive FDG scan . FDG-PET allow investigator obtain vivo imaging increase glycolysis know hallmark tumor aggressiveness . The aim phase I-II study evaluate efficacy toxicity PRRT 177Lu-DOTATATE ( Lu-PRRT ) associate metronomic chemotherapy Capecitabine patient affect aggressive FDG-positive gastro-entero-pancreatic NET . Moreover analyze effect capecitabine metronomic schedule level circulate angiogenetic factor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Histopathologic diagnosis inoperable metastatic gastroenteropancreatic neuroendocrine neoplasia . Conserved hematological , liver renal parameter : haemoglobin &gt; = 10 g/dL , absolute neutrophil count ( ANC ) &gt; = 1.5 x 109 /L , platelets &gt; = 100 x 109 /L , bilirubin â‰¤1.5 X UNL ( upper normal limit ) , ALT &lt; 2.5 X UNL ( &lt; 5 X UNL presence liver metastasis ) , creatinine &lt; 2 mg/dL . Age 18 year . Patients documented disease admit therapeutic phase diagnostic receptor imaging ( OctreoScan ) demonstrate significant uptake tumor ( grade 2 3 , accord preset scoring , grade 1= equal normal liver , grade2 = high normal liver , grade 3= high kidney spleen ) , may allow deliver low absorb dose normal organ high dose tumor . Patients document disease admit therapeutic phase 18FDG PET/CT positive SUV &gt; 2.5 least one documented lesion . Disease must measurable mean conventional imaging ( CT MRI ) . Before treatment clinical history data collect , physical examination perform diagnostic laboratory data examine . Patients must receive treatment ( e.g . chemo radiotherapy ) one month two month completion 177LuDOTATATE cycle . Patients must naive previous radionuclide treatment radiopeptides ( e.g . 111Inpentetreotide , 90YDOTATOC ) radiopharmaceutical ( e.s . 131IMIBG , 131I ) . Pregnancy/breastfeeding ( pregnancy test old 7 day mandatory ) . Assessed bone marrow invasion &gt; 25 % . Other concomitant neoplasm ( exclude situ basaliomas radically treat cervical cancer ) . ECOG score high 2 . Expectancy life shorter 6 month . Patients psychophysical condition suitable enter clinical study fulfilling requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>gastro entero pancreatic neuroendocrine tumor</keyword>
	<keyword>Radioisotope therapy</keyword>
	<keyword>177Lu-DOTATATE</keyword>
	<keyword>METRONOMIC CAPECITABINE</keyword>
</DOC>